AKB-9778 verfehlt primäre Endpunkte in Phase 2b Studie
endpts.com/...ips-up-in-mid-stage-diabetic-retinopathy-study/
- MK 53 Mio. $
- Cash 63 Mio. $
- Lizenzumsätze 20 Mio. $
- Verlust 10 Mio. $ (in 2018)
- Verlust in Q4/18 ~9 Mio. $
- Verlust in Q4/18 ~9 Mio. $
endpts.com/...ips-up-in-mid-stage-diabetic-retinopathy-study/
ir.aerpio.com/...=254540&p=irol-newsArticle&ID=2390090